Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $273.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target boosted by Wedbush from $240.00 to $273.00 in a research report report published on Thursday morning, Marketbeat reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other research firms also recently issued reports on ASND. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $246.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Raymond James Financial assumed coverage on Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price objective on the stock. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Stifel Nicolaus upped their price objective on Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $284.00.

Ascendis Pharma A/S Trading Down 0.8%

ASND opened at $216.32 on Thursday. The stock has a fifty day moving average price of $214.86 and a 200 day moving average price of $205.14. Ascendis Pharma A/S has a 1 year low of $124.06 and a 1 year high of $242.00. The stock has a market cap of $13.41 billion, a price-to-earnings ratio of -49.16 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds have recently added to or reduced their stakes in ASND. Advisory Services Network LLC bought a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $26,000. Leonteq Securities AG acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at about $36,000. First Horizon Advisors Inc. acquired a new stake in shares of Ascendis Pharma A/S during the second quarter worth about $41,000. Jones Financial Companies Lllp grew its position in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 113 shares during the period.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Management flagged growth momentum on the Q4 call and highlighted strong YORVIPATH uptake — a driver for near-term revenue expansion. Ascendis Pharma FY 2025 Results: More Than A Takeover Story
• Positive Sentiment: Quarterly revenue slightly beat consensus (company reported ~$290M vs. ~285M expected), supported by YORVIPATH sales highlighted in the earnings summary. Earnings Call Highlights
• Positive Sentiment: Wedbush raised its price target to $273 and kept an outperform stance — a meaningful analyst upgrade that implies upside from current levels. Wedbush Price Target Raise
• Positive Sentiment: Street coverage remains constructive overall — brokerages’ consensus is an average “Buy”, supporting near-term investor interest. Brokerage Ratings
• Neutral Sentiment: Independent investor outlets are comparing ASND to peers (Ionis) and discussing momentum; these pieces provide context but aren’t new company catalysts. AAII Comparison
• Neutral Sentiment: Full earnings-call transcripts and analyst writeups are available for deeper read — useful for conviction but not immediate market-moving on their own. Earnings Call Transcript
• Neutral Sentiment: Reported short-interest data in recent releases show zeros and a days-to-cover of 0.0 — likely a reporting/data anomaly rather than a real change in short exposure; monitor official filings for clarity.
• Negative Sentiment: EPS missed substantially: ASND reported a ($0.64) loss vs. consensus (~$-0.06), which is weighing on near-term sentiment despite the revenue beat. Earnings Summary / EPS Miss
• Negative Sentiment: Sector competition: news that BridgeBio’s moves are reshaping the achondroplasia landscape pressured shares across peers (BioMarin, Ascendis) as investors reassess competitive risk. BridgeBio Competitive News

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.